Pharmacokinetic/pharmacodynamic (PK/PD) parameters derived from animal and clinical models of infection are used to predict bacteriological efficacy. Growing evidence from the clinical setting supports the validity of these parameters in guiding antimicrobial therapy. For example, in otitis media and sinusitis, high bacteriological cure rates are obtained when serum concentrations of p-lactams and macrolides exceed the MIC of the infecting pathogen for at least 40% of the dosing interval. Likewise, the 24-hour AUC/MIC ratio is a good predictor of both bacteriological and clinical efficacy for azithromycin in otitis media and fluoroquinolones in bacterial pneumonia. The value of PKjPD relationships has been recognized by the National Committee for Clinical Laboratory Standards (NCCLS) as another important factor to consider when establishing susceptibility breakpoints. Recent changes to NCCLS breakpoints for oral p-lactams for Streptococcus pneumoniue reflect this. Also, PKjPD parameters may play a role in predicting the impact of an antibiotic on the development and spread of resistant organisms. In an era of increasing resistance, we should select agents and doses that provide drug concentrations that exceed the magnitude of the PKjPD parameter required both for efficacy and to combat the emergence and spread of bacterial resistance.
Introduction
Increasing antimicrobial resistance among common respiratory pathogens (e.g. Streptococcus pneumoniae, Haemophilus injluenzae and Moraxella catarrhalis) has the potential to reduce the efficacy of many oral drugs commonly used to treat respiratory infections (see Garau, 'Clinical failures: the tip of the iceberg?, this issue) with patient and societal consequences. Thus, there is a need for a move towards preferentially using only those agents with suthcient potency and pharmacokinetic characteristics that will provide clinical activity against sensitive and resistant bacterial pathogens.
In concert with this, measures to control colonization and infection with resistant organisms should also be undertaken.
The goal of antimicrobial therapy is to maximize bacterial killing-simply inhibiting the pathogen may allow persistent colonization, recurrence of infection or permit the spread of resistant pathogens between individuals (1). The pharmacology of antimicrobial therapy can be divided into two distinct components-pharmacokinetics (PK) and pharmacodynamics (PD) . PK refers to the absorption, distribution and elimination of drugs. These factors, combined with the dose regimen, determine the time course of antibiotic concentrations in serum which, in turn, (2) . The inter-relationship between PK and PD determines the dosing duration and total dose required for optimal antimicrobial activity. This report offers an overview of the inter-relationship between PKjPD and efficacy for the various antimicrobial agents used for the treatment of RTIs. The value of PKjPD parameters in predicting the impact of antibiotic dose regimens on the selection of antibiotic resistance or maintenance of resistant clones is also examined.
Nature of PK/PD parameters for common antibiotics
Over the past decade, a number of studies have evaluated the predictive nature of PKjPD parameters with regard to in vivo bacteriological eradication. Specific PKjPD parameters (e.g. peak'/MIC, AUC2/MIC ratio and time above MIC) have all been shown to be major determinants of 'Peak plasma concentration *Area under the serum concentration vwsus time curve with efficacy is largely dependent on whether bacterial killing is concentration or time dependent, and on whether there are prolonged, persistent effects (Table 1) . These prolonged persistent effects are known as the post-antibiotic effect (PAE) and the post-antibiotic sub-MIC effect and result in the persistent suppression of bacterial growth following exposure to an antimicrobial agent.
For p-lactams, macrolides and clindamycin, the duration of time that serum concentrations exceed the MIC (time above MIC) provides the most accurate prediction of bacteriological efficacy. In contrast, for drugs such as fluoroquinolones and azithromycin, the AUC/MIC ratio is most important.
Thus, even if a fluoroquinolone and a plactam had the same in vitro activity for a given pathogen, there would be marked differences in the PD that would be important in determining the optimal dose regimen (1).
Magnitude of PK/PD parameters governing antimicrobial efficacy /sLACTAMS
As /3-lactams have a kill rate that is independent of concentration, concentrations higher than the MIC or MBC do not greatly increase bacterial kill. Thus, the dosing regimens should maximize the duration of time that serum drug levels exceed the MIC (2,3). Studies performed in murine models of 5'. pneumoniae thigh and pneumonia infections, using amoxicillin + clavulanate, have shown that bactericidal activity occurs once the duration of time starts to exceed 40% above the MIC in a 24-or 48-hour period ( Fig. 1) (4, 5) . This requirement is independent of the infecting pathogen and its resistance profile.
The double tympanocentesis method has been a useful tool in investigating the clinical relevance of PKjPD parameters for otitis media. In this method, a sample of middle ear fluid is taken just prior to antimicrobial therapy and then again 4-6 days after therapy has commenced and during follow-up when a clinical relapse occurs. This technique allows the bacteriological efficacy of antimicrobials to be directly measured and compared. As a result, much of the clinical data that are available supporting the validity of PKjPD parameters comes from studies in acute otitis media. Some data are also available from studies in sinusitis. Here, a sample of sinus fluid is taken prior to antibiotic therapy and then again about 7-10 days after the start of therapy.
Using data from studies in both otitis media and sinusitis, time above MIC for each of the dose regimens was calculated from mean serum concentrations and the MICs for different organisms were taken from the literature. Figure 2 illustrates the relationship between the time above MIC and bacteriological cure for many plactam agents in these two infections.
High rates of bacteriological cure (> 80%) were achieved once the time above MIC exceeded 40%. Most of the S. pneumoniae isolates were penicillin susceptible, hence the high bacteriological cure rate, which approaches 100% (6). Interestingly, the effect of time above MIC on bacteriological efficacy was independent of infection, which further supports the general utility of PKjPD parameters in predicting bacteriological efficacy. Assuming that a time above MIC of at least 40% is required for optimal bacteriological efficacy, then the effect of increased MICs due to antimicrobial resistance can be predicted ( sinusitis. 0, n : S. pneumoniae; 0, 0: H. injuenzae; l , 0: otitis media; n , 0: acute maxillary sinusitis. Reproduced with permission (6).
coverage against a significant proportion of these strains, the other oral fl-lactams being largely ineffective (i.e. time> MICaa = 0). These predictions are supported by clinical data in otitis media. For example, in a study by Dagan et al., bacteriological efficacy with cefaclor (40 mg kg-' day-i) in cases due to penicillin-susceptible S. pneumoniae was 81% compared with 100% for amoxicillin (49.5 mg kg-' day-'). However, in those patients infected with penicillin non-susceptible S. pneumoniae, bacteriological efficacy with cefaclor was only 35%, but was still as high as 71% for amoxicillin against these strains (7). Similarly, in a separate study with amoxicillin/ clavulanate (45/6.4 mg kg-' day-') in children with otitis media, the drug was highly effective, even against strains with MICs of 2,~~grnl-' and higher (8).
For H. injluenzae, there are wide variations among the /?-lactams in the percentage of time above MIC achieved ( Table 2 ). Several of the cephalosporins (e.g. cefaclor, cefuroxime and cefprozil) do not provide sufficient serum levels to achieve a 40% time above MIC, and are unlikely to exhibit high bacteriological efficacy. Using the same study as above as an example, for those patients infected with H. injfuenzae, the bacteriological failure rate with cefaclor was 50% compared with 27% for amoxicillin (7). However, the failure rate with amoxicillin was 60% against strains producing p-lactamase compared with 21% for plactamase negative strains, clearly illustrating the effect of resistance on antimicrobial efficacy (7).
MACkOLIDES
For the older macrolides (e.g. erythromycin and clarithromycin), as for the p-lactams, time above MIC is predictive of bacteriological efficacy (3). For optimal efficacy, macrolide serum concentrations should exceed the MIC of the infecting pathogen for 40&50% of the dosing interval. Although the azalide, azithromycin, does not exhibit concentration-dependent killing, the AUC/MIC ratio correlates with bacteriological efficacy. This may be due to the much longer in vivo PAEs produced by azithromycin, in comparison with other macrolides or fl-lactams (2). For azithromycin, the 24-hour AUC/MIC ratio needs to exceed There is growing evidence that, even though MICs for macrolides against H. iq?uenzae may be in the 'susceptible' range (as defined by current MIC breakpoints), in vivo bacteriological efficacy is poor against this pathogen. For example, against strains of H. injluenzae with clarithromytin or erythromycin MICs of 4 ,ugml-', the time above MIC would be 0% of the dosing interval for both of these agents at standard dosing regimens. For azithromycin, a similar situation has been observed. For example, against H. irfluenzae with azithromycin MICs of 0.5->2pgmll' (i.e. susceptible), the rate of bacteriological failure was as high as 61%. Moreover, when only those isolates with MICs > 2 pg ml-' were included, bacteriological failure increased to 78% (8). This is consistent with PKjPD predictions, as an azithromycin MIC against H. injluenzae of 2pgmll' would give an AUC/MIC ratio of ~2, well below the value of 25 required for bacteriological efficacy.
FLUOROQUINOLONES
The 24-hour AUC/MIC ratio is predictive of bacteriological efficacy for the fluoroquinolones (3), and is independent of the dosing interval, the fluoroquinolone used and the site of infection (2) . The magnitude of this parameter required for bacteriological efficacy varies according to the infecting pathogen-for S. pneumoniae AUC/MIC needs to be 25-30. In comparison, for Gram-negative bacilli (e.g. Escherichia coli), particularly those causing nosocomial infections, the AUC/MIC ratio needs to reach 100; that is, serum levels need to average around four times the MIC over a 24-hour period (2) . as an important factor to consider when establishing susceptibility breakpoints. New NCCLS breakpoints, issued in January 2000, for oral p-lactams for S. pneumoniae reflect the impact of PKjPD relationships (Table 3 ) (17).
For fl-lactam antibiotics, only two oral agents were previously designated NCCLS breakpoints for S. pneumoniae-amoxicillin and cefuroxime (both 0.5 pgrnl-I). With a target PKjPD value of 40% time above MIC for predicted efficacy, a PKjPD breakpoint can be calculated. Thus, S. pneumoniae NCCLS susceptibility breakpoints were set at 2 pg ml-' for amoxicillin and 1 pg ml-' for cefuroxime to more accurately reflect the in vivo bacteriological efficacy of these agents. Breakpoints have also been set for cefaclor (1 pgmll'), cefprozil (2 pgml-') and cefpodoxime (0.5,ngml-I), though as yet there is no NCCLS breakpoint for cefixime (PK/PD breakpoint 0.5,ugmll'). For the azalide, azithromycin, in order to achieve an AUC/MIC ratio of 25, the PKjPD breakpoint for S. pneurnoniae would be 0.12 pg ml-'. This is two doubling dilutions lower than the current NCCLS breakpoint of 0.5 pg ml-'.
For the fluoroquinolones, NCCLS breakpoints are only available at present for levofloxacin (2 ,ug ml-'), sparfloxacin (0.5 pg ml-'), ofloxacin (2 pg ml-I), grepafloxacin (0.5 pg ml-') and trovafloxacin (1 pg ml-'). These breakpoints are generally in line with PKjPD breakpoints calculated to achieve a 24-hour AUC/MIC ratio of 25-30.
H. INFLUENZAE
There are varying degrees of discrepancy between NCCLS breakpoints for H. injuenzae and calculated PKjPD breakpoints for different antibiotic agents (Table 4) . For the /$lactams, cefaclor shows the greatest difference in NCCLS veTsus PKjPD breakpoint.
The clinical effect of this difference was shown in a recent double tympanocentesis study by Dagan et al. in patients with otitis media (18). With a dose of 40 mg kg-' day-' cefaclor, they reported a high bacteriological failure rate for H. injuenzae of 50% (15/30). This is despite all the H. inzuenzae isolates being susceptible to cefaclor using NCCLS breakpoints (18). From these findings, the investigators determined that the clinically relevant breakpoint for cefaclor was 0.25 pg ml-', which is closer to the PKjPD breakpoint (18).
For both clarithromycin and azithromycin, the PKjPD breakpoint is five doubling dilutions lower than the NCCLS breakpoint.
Again, there is evidence from studies in otitis media supporting the clinical relevance of the PK/ PD parameter. For example, in the same recent study as above, 17 of 35 (49%) patients treated with 10 mg kg-' day-' azithromycin experienced bacteriological failure (18). The low bacteriological efficacy of azithromytin against H. injuenzae has been confirmed in another recent study in which azithromycin (10 mg kg-' on day 1, then Smgkgg'dayy' for 4 days) failed to eradicate H. influenzae in 61% of patients (8). In both these studies, all isolates were susceptible to azithromycin using the NCCLS were carriers of susceptible and non-susceptible strains of S. pneumoniae, respectively. However, at the end of treatment, significantly fewer children receiving amoxicillin/clavulanate were carriers of S. pneumoniae-including PRSP-compared with those receiving ceftriaxone (41 versus 99, P<O.OOOl).
A total of 63 children in the ceftriaxone group were carriers of nonsusceptible S. pneumoniae compared with just 34 in the amoxicillin/clavulanate group (P = 0.02). This difference may be explained to some extent by the fact that, in the case of ceftriaxone, swabs were taken from the nasopharynx at 10 days. Thus, drug levels with a single dose of ceftriaxone were above the MIC for only about 2 of the 10 days, so the duration of time above MIC was actually inferior to that obtained with amoxicillin.
Based on the data above on the eradication of nasopharyngeal carriage of PSSP and PRSP, serum concentrations need to exceed the MIC for about 80-100% of the dosing interval to achieve high rates of eradication. Current dose regimens may not be sufficient to achieve this requirement. New formulations, which deliver higher doses, are being developed to ensure that target PK/ PD values can be reached. For example, a new 901 6.4mgkgg'dayy' suspension formulation of amoxicillin/ clavulanate has been developed specifically for this purpose. Data have not yet been reported on the effect of this formulation on nasopharyngeal carriage. However, initial bacteriological efficacy results in otitis media are encouraging (25). In a recently reported study, 351 patients with AOM had pathogens isolated at screening. Overall, 54% of the 146 isolates of S. pneumoniae detected were penicillin susceptible, with 17% intermediate and 29% resistant. Of the patients with S. pneumoniae infection, 114 had repeat typanocentesis that was positive for S. pneumoniae. Treatment with high-dose amoxicillin/clavulanate resulted in eradication of S. pneumoniae in 99% of these patients at end of therapy (25).
Inappropriate antibiotic therapy can increase the probability of continued nasopharyngeal carriage and the risk of harboring resistant strains. For example, a study conducted in children in Iceland found that the odds ratio for carriage of penicillin-resistant pneumococci, after three or more courses of antibiotic therapy, was 12 with erythromycin or co-trimoxazole, compared with only 6 for fl-lactams (26). This indicates that erythromycin was a more potent selector of penicillin resistance than p-lactams in this community. This is because the particular clone of S. pneumoniae in these individuals was resistant to multiple agents. Here, the use of one antibiotic class, in this case macrolides and co-trimoxazole, can select for resistance to another classes of agent, in this case penicillin (26).
Emergence or selection of resistant mutants
The application of pharmacodynamic concepts suggests that bacterial exposure to low and prolonged concentrations of antimicrobial agents may have a role in the selection of resistant strains. Analysis of macrolide prescribing and resistance patterns in S. pneumoniae indicates a correlation between increasing macrolide resistance and the use of newer, long-acting macrolides (e.g. azithromycin and clarithromycin) (27). These agents have long half-lives, and serum concentrations do not exceed the MIC throughout the dosing interval. This may increase the potential for the induction of antibiotic resistance. Further evidence of the impact that macrolides may have on resistance development comes from Iceland (28). As discussed above, in this country, the predominant drug-resistant S. pneumoniae clone (type 6B) is multiresistant to a number of agents and macrolides have been shown to select for penicillin resistance in this organism (26). The consumption of macrolides and co-trimoxazole has fallen by 30% since 1990. This has coincided with a decrease in penicillin-resistant S. pneumoniae from a peak prevalence of 20% in 1992 to 13% in 1997 (28). There was no major change in the use of p-lactams during this period (< 10% in their ability to achieve the PKjPD values necessary for bacterial eradication, particularly in the case of resistant strains. Appropriate antimicrobial choice (choice of agent, dose and duration) should be based on the ability to eradicate pathogens from the site of infection and from the nasopharynx using PKjPD principles and local susceptibility data as a guide to effective therapy.
In conclusion, the judicious use of antimicrobial agents should permit the clinician to prescribe from a selection of agents which maximize bacteriological and clinical cure, and which minimize the emergence and spread of resistant pathogens.
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